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ABSTRACT 
 
 Acute and chronic methylphenidate (MPD) administration was recorded 
simultaneously in freely moving adolescent rats previously implanted with permanent 
semi-?????????????????????????????????????????????????????????????????????????????
activity and for the locus coeruleus (LC) neuronal activity. The evaluation of neuronal 
?????????????????????????????????????????????????????sponse to chronic MPD exposure, 
with rats eliciting behavioral sensitization or behavioral tolerance. On experimental day 
(ED) 1, the locomotor and neuronal activity was recorded after saline (baseline) and 
MPD (0.6, 2.5, or 10.0 mg/kg) injection (i.p.). The rats were administered daily with a 
single dose of MPD for five consecutive days (ED2-ED6) to elicit behavioral 
sensitization or behavioral tolerance. Following three washout days with no drugs, the 
locomotor and neuronal activity recordings resumed on ED10 post saline and rechallenge 
MPD administration. The main findings were as follows. The same dose of chronic MPD 
administration elicited behavioral sensitization in some rats and behavioral tolerance in 
other rats. A total of 51.5%, 56.6%, and 86.3% of LC units responded significantly to 
acute 0.6, 2.5, and 10.0 mg/kg MPD respectively. A total of 51.5%, 72.4%, and 82.3% of 
LC units responded significantly by changing their baseline activity on ED10 compared 
  vi 
to that on ED1 in 0.6, 2.5, and 10.0 mg/kg MPD dose groups respectively. A total of 
53%, 67.1%, and 90.2% of LC units responded significantly to chronic 0.6, 2.5, and 10.0 
mg/kg MPD respectively. The LC neuronal population recording following acute MPD 
on ED1 and rechallenge MPD on ED10 from the rats eliciting behavioral sensitization 
was significantly different from the neuronal population recorded from the rats eliciting 
behavioral tolerance. Overall, these findings show that the same dose of chronic MPD 
can elicit behavioral sensitization or behavioral tolerance. We were able to verify our 
hypothesis that the LC units recorded from the rats eliciting behavioral sensitization 
responded significantly different to MPD from the rats eliciting behavioral tolerance. 
This correlation suggests that LC neuronal activity plays an important role in the 
expression of behavioral sensitization and behavioral tolerance by chronic MPD 
exposure. 
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IN T R O DU C T I O N 
 
 Attention-deficit/hyperactivity disorder (ADHD) is a behavioral disorder 
characterized by increased inattention, hyperactivity, and impulsivity (Newcorn, 2000; 
Volkow et al., 2005). ADHD has its onset in childhood and affects approximately 5-15% 
of school-aged children in the United States (Biederman et al., 1999; Goldman et al., 
1998). Pyschostimulants were first proposed to treat ADHD in 1937 and are currently 
used as first line management for ADHD symptoms (Challman and Lipsky, 2000; 
Eichlseder, 1985; Godfrey, 2009; Goldman et al., 1998; Swanson et al., 1999). 
Methylphenidate (MPD), commonly known as Ritalin, is one of the most prescribed 
drugs for the treatment of ADHD and works to reduce symptoms of inattention, 
hyperactivity, impulsivity, as well as aggressive and oppositional behaviors. MPD is also 
used as a cognitive enhancer to improve academic performances, social interactions, and 
for recreation (American Academy of Child and Adolescent Psychiatry, 1997; Godfrey, 
2009; Greely et al. 2008; Stix, 2009).  
 Abnormalities in the dopaminergic and noradrenergic system have been 
implicated in the pathophysiology of ADHD (Arnsten, 2006; Biederman, 2005; Del et al., 
2011; Kuczenski and Segal, 2001). MPD binds mainly to dopamine (DA) and 
norepinephrine (NE) transporters. This prevents the clearance of DA and NE from the 
synaptic cleft back to presynaptic terminals and suggests that this increase in the levels of 
synaptic DA and NE may account for the observed rewarding therapeutic effects of MPD 
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(Biederman and Spencer, 1999; Drouin et al., 2006; Kuczenski and Segal, 2002; Pliszka 
et al., 1996; Volkow et al., 1995, 2005).  
 Since children with ADHD are treated with MPD for many years (Anderson et al., 
1987; Eichlseder, 1985; Kollins, 2003; Levin and Kleber, 1995), concerns about the 
potential overuse of MPD have been raised in the media and scientific community 
(Accardo and Blondis, 2001; Kollins, 2003). MPD has a similar neuropharmacological 
profile to cocaine, possessing a chemical structure similar to amphetamine and 
methamphetamine, but differing by having a much lower rate of clearance from the brain 
(Kallman and Isaac, 1975; Patrick and Markowitz, 1997; Morse et al., 1995; Volkow et 
al., 1999). There are concerns today regarding the potential abuse of MPD usage leading 
to prescription abuse and/or serving as a gateway to the abuse of other drugs that could 
potentially elicit drug dependence similar to cocaine and amphetamine (Biederman et al., 
1998; Jaffe, 1991; Kollins et al., 2001; Kollins, 2003; Robbins, 2002). While some 
reports claim that MPD use may result in an increased risk for substance behavioral 
disorders, other reports demonstrate that psychostimulant exposure in adolescents 
protects them from a later substance use disorder (Biederman et al. 1999, Wilens et al., 
2003).  
 During early childhood, significant neurodevelopment known as synaptic pruning 
occurs. Synaptic pruning refers to a neurological regulatory process where there is crucial 
production and elimination of neurophils and neuronal connections (Levin and Kleber, 
1995). This raises additional concerns over the possible adverse effects of MPD while the 
brain is still going through developmental stages. It was reported that repeated treatment 
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with psychostimulants may initiate molecular, morphological, and behavioral modulation 
(Chao and Nestler, 2004; Dietz et al., 2009; Gaytan et al., 1997; Nestler, 2004; Yang et 
al., 2011) that can alter developmental processes and produce plasticities at the cellular 
level of the central nervous system (CNS), which can cause dependence, tolerance, and 
sensitization (Levin and Kleber, 1995). It has been reported that the same dose of MPD in 
some animals elicits behavioral sensitization; while in other animals, the same does of 
MPD elicits behavioral tolerance (Barron et al., 2009; Dafny and Yang, 2006; Jones and 
Dafny, Kuczenski and Segal, 2001; 2013; Tang and Dafny, 2013;Yang et al., 2000;). 
Behavioral tolerance refers to drug induced adaptations that result in diminishing effects 
after repeated administration, while behavioral sensitization, or reverse tolerance, is 
characterized by progressive augmentation of behavioral responses to the same drug dose 
following its recurring use (Askenasy et al., 2007; Dafny and Yang, 2006; Kalivas et. al., 
1988; Robinson, 1984; Wiley, 1971). The consequences of long-term use of 
psychostimulants such as MPD as treatment for ADHD in the developing brain of 
adolescents are not clearly known, making it important to investigate the effects of MPD 
on adolescent rats.  
 Knowing that psychostimulants exert their effects on the CNS, it is essential to 
study the effects of MPD on the brain itself. Even though both DA and NE are involved 
in the pharmacological action of MPD, the main focus in the treatment of ADHD appears 
to rely heavily on the DA system. Data on the NE system is limited when examining the 
effects of MPD treatment. It has been shown that MPD treatment increases extracellular 
NE levels by binding to NE transporters (Biederman and Spencer, 1999; Kuczenski and 
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Segal, 2001, 2002; Pliszka et al., 1996). Increases in NE concentration are known to 
affect performance of attention and maintain arousal and alertness of the CNS, which is 
compromised in ADHD patients (Biederman and Spencer, 1999; Drouin et al., 2006; 
Pliszka et al., 1996). The locus coeruleus (LC) is the principal CNS site that synthesizes 
NE. LC noradrenergic neurons extensively project to widespread areas of the brain and 
spinal cord regulating the functions of arousal and autonomic activity (Amaral and 
Sinnamon, 1977; Moore and Bloom, 1979). Several studies indicated that the 
administration of acute and chronic MPD decreased the firing rate of spontaneous activity 
of LC neurons in animals, suggesting electrophysiological tolerance (Devilbiss and 
Berridge, 2006; Lacroix and Ferron, 1988; Olpe et al., 1985), while another study 
conducted with adult rats showed that the majority of LC neurons significantly increased 
their firing rate after acute and chronic MPD administration, demonstrating that enhanced 
LC neuronal activities play a significant role in the effect of MPD (Tang and Dafny, 
2012).  
 The aim of the current study is to examine the tendency for chronic administration 
of MPD to elicit behavioral sensitization in some rats, but behavioral tolerance in others, 
specifically in regards to the effects of MPD on the LC and the NE system in un-
anesthetized, freely behaving adolescent rats previously implanted with permanent semi-
microelectrodes. The avoidance of anesthesia is critical, as noradrenergic neurons in the 
LC have been shown to be the ta??????????????????????????????????????????????? ?????
effect (Kushikata et al., 2011). Additionally, since NE is involved in the locomotor effect 
of MPD (Tyler and Tessel, 1980), it stands to reason that locomotor activity is a viable 
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outcome measurement of the effect of MPD on the LC. Measuring locomotor activity on 
anesthetized rats would be impossible, making it of extreme importance that the rats not 
only remain un-anaesthetized, but that they are also unrestricted in their movement. Since 
most of the previous neurophysiological studies on the mechanism of MPD have been 
done in vitro or in vivo under anesthesia condition, which can modulate the drug affect 
(Price, 1975), and without monitoring the behavior of animals, the present study was 
performed on freely behaving rats previously implanted bilaterally with semi-
microelectrodes within the LC.  
 The hypothesis of this study is that the same repetitive dose of MPD will elicit 
behavioral sensitization in some rats and behavioral tolerance in other rats, and that the 
LC neuronal activity recordings from the rats displaying behavioral sensitization to 
chronic MPD exposure will respond differently to MPD compared to the neuronal 
activity recordings from the rats displaying behavioral tolerance to chronic MPD 
exposure. To our knowledge, this study is the only one that reports the chronic dose 
response of MPD on LC neuronal activity in adolescent, freely behaving rats and 
????????????????????????????????????????????????????????????????????????????????????
chronic MPD. These results should provide important insights into the elucidation of the 
mechanism of action of MPD on the LC-NE system.  
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M A T E RI A LS A ND M E T H O DS: 
 
Animals  
 Adolescent Sprague-Dawley rats weighing 80 grams were each housed 
individually in a home cage in the animal facility room with free access to food pellets 
and water. They were given 2-4 days for acclimation prior to semi-microelectrode 
implantation. Room temperature of 21± 2°C was maintained with a relative humidity of 
58-64%. The room was under a 12hr: 12hr light/ dark cycle with the lights on at 06:00 
AM. After electrode implantation, the rats were returned to their home cage that also 
served as their test cage for the behavioral and electrophysiological recordings. 
All experimental procedures were approved by the University of Texas Health Science 
Center Animal Welfare Committee and in accordance with the National Institute of 
Health Guide for Care and Use of Laboratory Animals. 
 
E lectrode Implantation 
 Following the last day of the acclimation period, the rats were anesthetized with 
??? ???????????????????????????????????????????????????????????????????????????????????
lidocaine hydrochloride topical gel was applied to the shaved area for local anesthesia. 
The rats were then placed into a stereotaxic apparatus to continue on with the procedure. 
A 1 inch incision was made on the scalp, retracting the muscle from the cranium so that 
the skull could be exposed. Bilateral holes were drilled above the LC at 9.3 mm posterior 
to bregma and 1.0 mm lateral to midline, using Paxinos and Watson (1986) brain atlas 
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coordinates and an additional hole was drilled above the frontal sinus to serve as the 
reference electrode. Two twisted Nickel-Chromium electrodes (60?m in diameter; 
Diamel coated insulation except at the tip, each secured to a 1 cm copper connector pin) 
were implanted into each hemisphere of the LC. During electrode implantation, LC unit 
activity was monitored and electrodes were fixed into the skull when the spike activity of 
signal to noise ratio exhibited at least 3:1. If neuronal activity showed less than 3:1 signal 
to noise ratio, the electrodes were moved down in increments of about 5?m until they 
exhibited spike activity with proper signal to noise ratio. The copper pins of all the 
electrodes were attached to an Amphenol plug, which were permanently fixed to the skull 
with dental acrylic cement. The rats were allowed to recover from this surgical procedure 
for five to seven days. Everyday during the recovery period for two to three hours, the 
rats were allowed to acclimate to their testing cage in the Faraday cage while being 
connected to a wireless head stage transmitter  (Triangle BioSystems Inc., TBSI, 
Durham, NC, USA) allowing the rats to move freely around the testing cage. The 
wireless head stage transmitter weighing 4.5 grams was attached to the electrode pins of 
the skull cap. The TBSI head stage sent neuronal signals (sampling rates up to 200 kHz) 
to a receiver connected to Cambridge Electronic Design (CED) analog to digital 
converter (Micro1401-3; CED) that stored the recorded data on a PC for offline 
evaluation using Spike 2 version 7 (CED) software. 
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Drugs 
 The methylphenidate hydrochloride used was obtained from Mallinckrot Inc. 
(Hazelwood, MO, USA). MPD doses of 0.6, 2.5, and 10.0 mg/kg were used; MPD was 
dissolved in 0.9% isotonic saline solution and were calculated as freebase in preparation. 
Control injections administered i.p. consisted of 0.8 ml isotonic saline solution (0.9% 
NaCl). All MPD injections were equalized to a volume of 0.8 ml with 0.9% saline to 
keep injection volumes the same for all of the rats and for all of the MPD doses. MPD 
doses of 0.6, 2.5, and 10.0 mg/kg were selected for this study based on previous MPD 
dose response protocol testing behavioral and neurophysiological sensory, which evoked 
potential from 0.1 to 40.0 mg/kg MPD administration (Algahim et al., 2009; Gaytan et 
al., 1997, 2000; Lee et al., 2009; Podet et al., 2010; Yang et al. 2003, 2006a, b, c, d, 
2007).   
 
Experimental Protocol  
 The rats were randomly divided into four groups: saline (control), 0.6, 2.5, and 
10.0 mg/kg MPD treatment groups. On experimental day one (ED1), the rats were placed 
with their home cage (testing cage) in a Faraday cage to limit noise during recording 
sessions. The wireless head stage (TBSI) was connected to the electrode pins of the skull 
cap and the rats were allowed to acclimate for 30 minuets before the recording session. 
During the 30 minute acclimation period, the recording software parameters were 
selected and the injections of both saline and MPD were prepared. After the 30-minute 
acclimation period, the rats received a standardized saline injection of 0.8 ml and the 
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neuronal and behavioral/ locomotive activity was concomitantly recorded for one hour, 
this recording served as baseline (BL) activity. The rats then received a saline, 0.6, 2.5, or 
10.0 mg/kg MPD injection and the neuronal and behavioral/locomotive activity 
recordings continued for an additional hour post injection (Table 1). On ED2 through 
ED6, the rats received daily injections of either saline (control group), or a single dose of 
0.6, 2.5, 10.0 mg/kg MPD in their home cage to initiate the MPD chronic effect. On ED7 
through ED9, the rats went through a wash out period; on these experimental days, no 
injections were given. On ED10, the standardized saline injection was given and the 
neuronal and behavioral/ locomotive activity was recorded for an hour. This was 
followed by a rechallenge administration of either saline or MPD similar to ED1 and 
recordings continued for an additional hour.  
 
Table 1: Summary Of The Exper imental Protocol 
Four groups were used: saline, 0.6, 2.5, and 10.0 mg/kg MPD. On experimental day 1 (ED1), 
the behavioral and neuronal activities of the rats were recorded for one hour following saline 
injection and for another hour after the initial saline, 0.6, 2.5, or 10.0 mg/kg MPD was 
administered and recorded. On ED2?ED6, the rats were only given an injection of the specified 
dose. ED7?ED9 are washout days where the rats were not given an injection of any kind. On 
ED10, the rats were given another dose of saline and recording resumed for 1 hour followed by 
the designated dose identical to that given on ED1 and recording resumed for 1 hour.  
 
T reatment E D1 E D2-E D6 E D7-E D9 E D10 
Saline Saline/saline Saline Washout Saline/saline 
0.6 mg/kg Saline/ 0.6 0.6 Washout Saline/ 0.6 
2.5 mg/kg Saline/ 2.5 2.5 Washout Saline/ 2.5 
10 mg/kg Saline/ 10 10 Washout Saline/ 10 
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E lectrophysiological And Behavioral Apparatus 
 The LC neuronal activity and behavioral activity were recorded simultaneously 
using a wireless recording system (Triangle BioSystems Inc., TBSI, Durham, NC, USA) 
and an open field computerized animal activity system (Opto-M3, Columbus Instruments, 
Columbus, OH). The TBSI system consisted of a wireless head stage weighing 4.5g and a 
remote receiver. The head stage was attached to the electrode pins of the skull cap of the 
rat and sent neuronal activity signals to a receiver connected to the Cambridge Electronic 
Design (CED) analog to digital converter (Micro 1401-3; CED, Cambridge, UK) that 
stored the digitized data on a PC using the Spike 2 Version 7 software for offline 
?????????????????????????????????????????????????????????????????????????????????
apparatus allowing for the recording of the rats in their home cage. The home cage and 
recording system were located inside a Faraday cage to limit noise and outside 
interference. The open field system had 16 x 16 infrared beams and their sensors were set 
5 cm above the cage floor on the opposite side. The open field apparatus has been 
previously described in detail (Gaytan et al., 2000; Yang et al., 2003, 2006a, 2007). The 
activity monitoring system checked each of the sensory beams at 100 Hz frequency to 
determine if the beams were interrupted. Interrupted beams were compiled by the 
software and downloaded to a PC every 10 minutes. The program organized the beam 
interruptions into different locomotor behaviors such as horizontal activity (HA) and 
number of stereotypic (NOS) activity. The HA was used to record the overall amount of 
locomotor activity, while the NOS counted the number of repetitive movement episodes 
with at least one-second interval before the beginning of another movement. The 
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objective of the behavioral recordings was to distinguish rats that expressed behavioral 
sensitization from rats that expressed behavioral tolerance following repetitive MPD 
exposure.  
 
Data Analysis 
Behavioral Data 
 Locomotor activity was recorded and summed into 10 minute bins for a total of 
60 minutes after the saline injection and another 60 minutes of behavioral activity was 
recorded following MPD injection (12 bins total) on ED1 and again on ED10 following 
saline and MPD exposure (Table 1). Several comparisons were made in each dose group. 
(1) Locomotor activity following MPD administration on ED1 was compared to ED1 
baseline (saline) activity to analyze the acute effect of MPD. (2) Locomotor activity 
following saline injection on ED10 was compared to the locomotor activity following 
saline injection on ED1 to analyze whether the baseline locomotor activity changed after 
six daily (chronic) MPD administration and three washout days. (3) Locomotor activity 
following MPD administration on ED10 was compared to the locomotor activity 
following MPD administration on ED1 to indicate whether behavioral sensitization or 
behavioral tolerance was expressed. Significant differences among individuals were 
discovered by the critical ratio test (C.R. = (E ? C)/( ??????????±1.96 = p <0.05) where C 
is the control and E is the drug activity. A critical ratio (CR) value more than 1.96 
suggested that MPD elicited significant increased activity, indicating behavioral 
sensitization. A CR value more than ? 1.96 suggested that MPD elicited significant 
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decreased activity compared to the initial drug effects, indicating behavioral tolerance. 
Each rat was individually grouped by expressing either behavioral sensitization or 
behavioral tolerance. Significant differences among the groups (treatment days and drug 
dose) was discovered using a two-way ANOVA where p < 0.05 was accepted as the 
minimal level of significance. 
Neuronal Data  
 The CED Spike 2.7 software was used for spike sorting and analysis. The 
program sorts spikes based on spike waveform shape and amplitude by setting parameters 
for templates. Data was captured by the program and processed using low and high pass 
filters (0.3-3 kHz). There were two discriminator levels: one for positive going spikes and 
another for negative going spikes. Spikes with peak amplitudes within the window were 
used to create templates, which required 1,000 waveform data points. The algorithm used 
to capture a spike pattern allows the extraction of templates that provide high 
dimensional reference points that can be used to perform accurate spike sorting, 
regardless of the influence of noise, false threshold crossing, and waveform overlap.  All 
temporally displaced templates are compared with the incoming selected spike event to 
find the best fitting template that yields the minimum residue variance. A template 
matching procedure is then used, when the distance between the template and waveform 
exceeds some threshold (80%), the waveforms are rejected to allow the spike sorting 
accuracy in the reconstructed data of about 95%. These parameters of spike sorting for 
each electrode on ED1 were sorted and reclassified for activity sorting on ED10. This 
ensured that the spike amplitude and pattern form were the same on ED1 and ED10 
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following saline and MPD administration. Spikes with peaks outside of these parameters 
were rejected. Statistical comparisons were made for each LC unit as follows: (1) LC unit 
activity after initial MPD administration was compared to LC unit activity following 
saline administration (baseline activity) on ED1; (2) LC unit baseline activity on ED10 
was compared to LC unit baseline activity on ED1; (3) LC unit activity after MPD 
administration on ED10 was compared to the unit activity following initial MPD on ED1. 
Statistical significance between the above comparisons for each LC unit was determined 
by the critical ratio test (C.R. = (E ? C)/( ??????????±1.96 = p <0.05) where C is the 
control and E is the drug activity. Critical ratio values of more than +1.96 proved that the 
unit showed significant increase in activity after MPD administration. On the other hand, 
critical ratio values of more than -1.96 proved that the unit showed significant decrease in 
activity after MPD administration. The data analysis described above was also 
???????????????????????????????????????????????????????????????????????????????????????
dose of MPD treatment as follows: (1) electrophysiological data of all LC units; (2) 
electrophysiological data recorded from rats expressing behavioral sensitization; (3) 
electrophysiological data recorded from rats expressing behavioral tolerance. 
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Histological Verification Of E lectrode Placement 
 After the completion of data recording, the rats were overdosed with sodium 
pentobarbital. The rats were perfused intracardially with 10% formaldehyde solution 
containing 5% potassium ferrocyanide. A 50 ?A DC current was passed through the tip 
of each electrode for 30 seconds to create a small lesion in order to identify the electrode 
location. The brain was then extracted from the skull and stored in 10% formaldehyde for 
subsequent histological processing. The position of the electrode tip was confirmed by 
the location of the lesion and the Prussian blue spot (Figure 1) using Rat Brain Atlas 
coordinates (Paxinos and Watson, 1986).  
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F igure 1:  Location Summary Of The L C Recorded E lectrodes 
 
The lower photo shows a representative histological section and the location of two electrode tops 
within the LC (white arrow indicates the electrode location). The photos are reconstructs 
histologically sketched and summarize the electrode tip placements. The rat atlas plates represent 
the LC in serial coronal sections. The numbers next to each section represents the posterior 
distance (mm) from bregma. The black dots are designated to represent electrode placement of 
those that were found in the LC (Tang and Dafny, 2012).  
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R ESU L TS 
 
 Only data from electrodes confirmed to be within the LC and exhibiting similar 
amplitude and waveform at ED1 and ED10 recording sessions were included. A total of 
113 rats were conducted in this experiment; 11, 28, 31, and 43 rats were treated with 
saline (control), 0.6, 2.5, and 10.0 mg/kg MPD respectively and a total of 220 LC units 
were recorded, 27, 66, 76, and 51 LC units were evaluated from saline (control), 0.6, 2.5, 
and 10.0 mg/kg MPD groups respectively (Table 1). 
 
Behavior  
 Eleven rats were treated only with saline (control). Following acute and repetitive 
saline administration, the locomotor activity (HA, and NOS) evaluated from ED10 
compared to ED1 expressed similar locomotor activity with insignificant variations. This 
confirms that neither saline nor handling had an effect on behavioral activity (Figure 2). 
Therefore, the recordings after saline administration on ED1 can be used as the control 
and any significant changes from baseline after drug administration is the result of the 
effects of MPD. The acute effect of MPD administration showed a positive correlation of 
dose response and increases in locomotor activity; with increasing MPD doses, more 
locomotor activity was observed. After six daily MPD exposures and three washout days, 
the baseline activity on ED10 increased when compared to the baseline activity on ED1. 
MPD rechallenge on ED10 compared to initial MPD on ED1 generally elicited 
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behavioral tolerance in all of the rats in the 2.5 mg/kg MPD dose group while in the 
higher MPD dose group of 10.0 mg/kg, the rats elicited behavioral sensitization. 
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F igure 2: Total Distance Activity Summary For The Saline (Control) G roup 
 
Total distance activity summary of the control group (N=11) after saline administration on 
experimental day one (ED1) and ED10. On each experimental day, saline was injected and 
behavioral activity was recorded for one hour. This was followed by a second saline injection and 
again the behavioral activity was recorded for another hour. There were no significant differences 
when comparing between the activity following the first and second saline injections on ED1 and 
ED10. 
 
 There were no observable significant changes in the behavioral activity in the 28 
rats treated with 0.6 mg/kg MPD when grouped together for either the acute or chronic 
exposures to MPD. When grouped together there were also no significant changes in 
behavioral activity when comparing the baseline activity on ED10 (after six daily 0.6 
mg/kg MPD exposures and three washout days) to the baseline activity on ED1 (Figure 
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3). When the rats were separated based on their individual responses to chronic MPD 
exposure, there were 14 rats that exhibited behavioral sensitization to 0.6 mg/kg MPD 
rechallenge on ED10 compared to MPD on ED1 using the C.R. test. These rats did not 
respond significantly to acute MPD exposures on ED1, but significantly (p < 0.05) 
increased behavioral activity to MPD rechallenge on ED10 using the ANOVA test 
(Figure 3 Sensitized). Using the C.R. test, there were also 14 rats that exhibited 
behavioral tolerance to 0.6 mg/kg MPD rechallenge on ED10 compared to MPD on ED1. 
On ED1, these rats exhibited significant (p < 0.05) increases in their locomotor activity 
after acute MPD exposure, but exhibited significant (p < 0.05) decreases in their 
locomotor activity on ED10 following MPD rechallenge using the ANOVA test (Figure 3 
Tolerant).  
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F igure 3: Total Distance Activity Summary For The 0.6 mg/kg MPD Dose G roup 
 
This figure summarizes the behavioral activity of the 0.6 mg/kg MPD dose group following acute 
and chronic injections. The activity for all of the rats grouped together (N = 28) is shown on the 
left part of the histogram with comparisons made between ED1 baseline activity, the ED1 activity 
following MPD injection, ED10 baseline activity, and the ED10 activity post MPD injection. On 
the middle and right side of the histogram, the rats are broken into two subgroups, those 
individual rats that exhibited behavioral sensitization (N = 14) and those individual rats that 
exhibited behavioral tolerance (N = 14).  
 
 
 There were 31 rats treated with acute and chronic 2.5 mg/kg MPD. When grouped 
together, acute MPD exposure exhibited significant (p < 0.05) increases in behavioral 
activity, while chronic MPD exposure exhibited significant (p < 0.05) decreases in 
behavioral activity when ED10 was compared to the initial MPD exposure on ED1 
(Figure 4). When the rats were separated based on their individual response to MPD, 
there were 22 rats that exhibited behavioral sensitization to 2.5 mg/kg MPD rechallenge 
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on ED10 compared to MPD on ED1 using the C.R. test. As a group, using the ANOVA 
test, these 22 rats significantly (p < 0.05) increased their locomotor activity to acute MPD 
administration and exhibited a further significant (p < 0.05) increase in locomotor activity 
following the rechallenge dose of 2.5 mg/kg MPD on ED10 compared to the initial 
response on ED1 (Figure 4 Sensitized). There were nine rats that exhibited behavioral 
tolerance to 2.5 mg/kg MPD rechallenge on ED10 compared to MPD on ED1 using the 
C.R. test. These nine individual rats exhibited a significant (p < 0.05) increase in 
behavioral activity to acute MPD and then exhibited a significant (p < 0.05) decrease in 
activity following the rechallenge dose of 2.5 mg/kg MPD on ED10 compared to the 
effect of MPD on ED1 using the ANOVA test (Figure 4 Tolerant).  The nine rats that 
elicited behavioral tolerance to the rechallenge MPD exposure on ED10 responded to 
acute MPD significantly (p < 0.05) higher compared to the 22 rats the expressed 
behavioral sensitization.  
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F igure 4: Total Distance Activity Summary For The 2.5 mg/kg MPD Dose G roup 
 
This figure summarizes the behavioral activity of the 2.5 mg/kg MPD dose group following acute 
and chronic injections. The activity for all of the rats grouped together (N = 31) is shown on the 
left part of the histogram with comparisons made between ED1 baseline activity, the ED1 activity 
following MPD injection, ED10 baseline activity, and the ED10 activity post MPD injection. On 
the middle and right side of the histogram, the rats are broken into two subgroups, those 
individual rats that exhibited behavioral sensitization (N = 22) and those individual rats that 
exhibited behavioral tolerance (N = 9).  
 
 When grouped together, the 43 rats that were treated with 10.0 mg/kg MPD 
showed a significant (p < 0.05) increase in behavioral activity following acute MPD 
exposure on ED1 and showed further significant (p < 0.05) increases in behavioral 
activity following the rechallenge MPD dose of 10.0 mg/kg using the ANOVA test 
(Figure 5). When the rats were separated based on their individual responses to chronic 
MPD exposure using the C.R. test, there were 37 individual rats that exhibited behavioral 
sensitization to 10.0 mg/kg MPD rechallenge on ED10 compared to MPD on ED1.  
These rats responded significantly (p < 0.05) to acute MPD exposure on ED1 by 
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increasing their locomotor activity and further exhibited significant (p < 0.05) increases 
in behavioral activity to MPD rechallenge on ED10 using the ANOVA test (Figure 5 
Sensitized). There were six individual rats that exhibited behavioral tolerance to 10.0 
mg/kg MPD rechallenge on ED10 compared to initial MPD on ED1. On ED1, these rats 
elicited a significant (p < 0.05) increase in their behavioral activity after acute MPD 
exposure; the MPD rechallenge dose of 10.0 mg/kg on ED10 resulted in significantly (p 
< 0.05) less behavioral activity compared to ED1 using the ANOVA test (Figure 5 
Tolerant).  
 
F igure 5: Total Distance Activity Summary For The 10.0 mg/kg MPD Dose G roup 
 
This figure summarizes the behavioral activity of the 10.0 mg/kg MPD dose group following 
acute and chronic injections. The activity for all of the rats grouped together (N = 43) is shown on 
the left part of the histogram with comparisons made between ED1 baseline activity, the ED1 
activity following MPD injection, ED10 baseline activity, and the ED10 activity post MPD 
injection. On the middle and right side of the histogram, the rats are broken into two subgroups, 
those individual rats that exhibited behavioral sensitization (N = 37) and those individual rats that 
exhibited behavioral tolerance (N = 6).  
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E lectrophysiology 
The E ffect O f MPD On The Neuronal Activity O f L C Units 
 A total of 220 units were recorded and evaluated from 55 electrodes (4 electrodes/ 
rat).  The 220 units were confirmed histologically to be within the LC and exhibited 
similar amplitude and waveform at ED1 and ED10. The neuronal activity of 27, 66, 76, 
and 51 LC units were evaluated from saline (control), 0.6, 2.5, and 10.0 mg/kg MPD 
groups respectively (Table 1). The effects of the saline injection were recorded in 27 LC 
units to obtain the control recordings for animal handling and the injection volume. In 
general, single and multiple saline injections did not significantly change the LC neuronal 
activity (Table 2). These observations revealed that any significant change following 
MPD exposure was considered as an effect of the drug.  
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Table 2: Effect Of Saline And MPD On A ll L C Neuronal Activity 
 
This table summarizes the number of LC units responding to three different acute and chronic 
saline and MPD exposures to 0.6, 2.5, and 10.0 mg/kg. The percentages shown next to the 
numbers summarizes the percentage of units that responded, i.e. total responsiveness. MPD = 
methylphenidate; ED = experimental day; BL = baseline activity; vs. = compare.  
 
 
 G roups  Units  Increase  Decrease  Unresponsive  
A.  Saline  27 0 (0%) 3 (11.1%) 24 (88.9%) 
Acute  0.6 mg/kg 66 14 (21.2%) 20 (30.3%) 32 (48.5%) 
Effect  2.5 mg/kg  76 27 (35.5%) 16 (21.1%) 33 (43.4%) 
 10 mg/kg  51 38 (74.5%) 6 (11.8%) 7 (13.7%) 
      
B.  Saline  27 2 (7.4%) 2 (7.4%) 23 (85.2%) 
ED10 BL  0.6 mg/kg 66 14 (21.2%) 20 (30.3%) 32 (48.5%) 
vs.  2.5 mg/kg  76 30 (39.5%) 25 (32.9%) 21 (27.6%) 
ED1 BL 10 mg/kg  51 35 (68.6%) 7 (13.7%) 9 (17.7%) 
      
C. Saline 27 1 (3.7%)  3 (11.1%) 23 (85.2%) 
MPD ED10 0.6 mg/kg 66 21 (31.8%) 14 (21.2%) 31 (46%) 
vs.  2.5 mg/kg 76 29 (38.2%) 22 (28.9%) 25 (32.9%) 
MPD ED1 10 mg/kg 51 31 (60.8%)  15 (29.4%) 5 (9.8%) 
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F igure 6: Representative Sequential F requency F iring Rates Of Two L C Units Following 
Acute 10.0 mg/kg MPD 
 
Both graphs show the neuronal unit activity post saline for 60 minutes, followed by the neuronal 
activity after MPD on ED1 for 60 minutes. Arrow indicates the time of 10.0 mg/kg MPD 
administration. The top graph (A) shows the LC unit exhibited an increase in firing rate activity 
to acute MPD administration compared to the baseline activity. The bottom graph (B) shows the 
LC unit exhibited a decrease in firing rate activity to acute MPD administration compared to the 
baseline activity.  
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Acute E ffect O f MPD In A ll Recorded Rats  
 A total of 193 LC units were evaluated following single doses of MPD 
administration and compared to their baseline activity. 51.5% (34/66), 56.6% (43/76), 
and 86.3% (44/51) of the recorded LC units responded significantly by changing their 
firing rate to 0.6, 2.5, and 10.0 mg/kg MPD exposure respectively (Table 2A, Acute 
Effect). 21.2% (14/66), 35.5% (27/76), and 74.5% (38/51) of the recorded LC units 
exhibited significant increases (Figure 6A) in their activity (critical ratio test, C.R. > 
+1.96), while 30.3% (20/66), 21.1% (16/76), and 11.8% (6/51) of the recorded LC units 
exhibited significant decreases (Figure 6B) in their activity after acute administration of 
0.6, 2.5, 10.0 mg/kg MPD respectively (critical ratio test, C.R. > -1.96).  
 
Acute E ffect O f MPD On The L C Units Recorded F rom Behavioral Sensitized Rats  
 Table 3 summarizes the acute effect of MPD on 69 LC units recorded from the 
rats exhibiting behavioral sensitization following repetitive MPD exposure. A total of 58 
out of 69 units responded significantly ( p < 0.05) by changing their firing rate; 77.8% 
(7/9), 85.7% (18/21), and 84.6% (33/39) of the LC units significantly changed their 
neuronal discharges either by increasing or decreasing their activity following acute 0.6, 
2.5, and 10.0 mg/kg MPD respectively. 66.7% (6/9), 57.1% (12/21), and 71.8% (28/39) 
of LC units responded to MPD by significantly increasing (critical ratio test, C.R. > 
+1.96) their activity after acute administration of 0.6, 2.5, and 10.0 mg/kg MPD 
respectively, while 11.1% (1/9), 28.6% (6/21), and 12.8% (5/39) of LC units responded 
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to MPD by significantly decreasing (critical ratio test, C.R. > -1.96) their firing rate after 
acute administration of 0.6, 2.5, and 10.0 mg/kg MPD respectively. 
 
Table 3: Acute E ffect Of MPD On L C Units In Behavioral Sensitization And Tolerance 
Rats  
 
This table summarizes the acute effect of MPD on 69 LC units recorded from the rats exhibiting 
behavioral sensitization following repetitive 0.6, 2.5, and 10.0 mg/kg MPD exposure and the 
acute effect of MPD on 124 LC units recorded from the rats exhibiting behavioral tolerance 
following repetitive 0.6, 2.5, and 10.0 mg/kg MPD exposure.  
 
G roups    Behavioral    Units    Increase    Decrease   No change   
0.6 mg/kg 
MPD   Sensitization    9   6 (66.7%)   1 (11.1%)   2 (22.2%)  
   Tolerance    57   8 (14%)   19 (33.3%)   30 (52.7%)  
                 
2.5 mg/kg 
MPD   Sensitization   21   12 (57.1%)   6 (28.6%)   3 (14.3%)  
   Tolerance   55   15 (27.3%)   10 (18.2%)   30 (54.5%)  
                 
10.0 mg/kg 
MPD   Sensitization   39   28 (71.8%)   5 (12.8%)   6 (15.4%)  
   Tolerance   12   10 (83.3%)   1 (8.3%)   1 (8.3%)  
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Acute E ffect O f MPD On The L C Units Recorded F rom Behavioral Tolerance Rats  
 Table 3 also summarizes the acute effect of MPD on LC units recorded from the 
rats exhibiting behavioral tolerance following repetitive MPD exposure. 47.3% (27/57), 
45.5% (25/55), and 91.6% (11/12) of the LC units significantly changed their neuronal 
discharges either by increasing or decreasing their activity following acute 0.6, 2.5, and 
10.0 mg/kg MPD respectively. 14% (8/57), 27.3% (15/55), and 83.3% (10/12) of LC 
units responded to MPD by significantly increasing (critical ratio test, C.R. > +1.96) their 
activity after acute administration of 0.6, 2.5, and 10.0 mg/kg MPD respectively, while 
33.3% (19/57), 18.2% (10/55), and 8.3% (1/12) of LC units responded to MPD by 
significantly decreasing (critical ratio test, C.R. > -1.96) their firing rate after acute MPD 
compared to their baseline activity in the 0.6, 2.5, and 10.0 mg/kg MPD treated group 
respectively. 
 
Comparing E D10 Baseline Activity To E D1 Baseline Activity In A ll Recorded Rats  
 The baseline neuronal activity on ED10 (after six daily MPD exposures and three 
washout days) was compared to ED1 baseline neuronal activity. A total 51.5% (34/66), 
72.4% (55/76), and 82.3% (42/51) of the recorded LC units exhibited a significant change 
by either increasing (critical ratio test, C.R. > +1.96) or decreasing (critical ratio test, 
C.R. > -1.96) their baseline activity on ED10 compared to their baseline activity on ED1 
in 0.6, 2.5, 10.0 mg/kg MPD treated groups respectively (Table 2B, ED10 BL vs. ED1 
BL). A total of 21.2% (14/66), 39.5% (30/76), and 68.6% (35/51) of the LC units showed 
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a significant increase (Figure 7A) in baseline activity, while 30.3% (20/66), 32.9% 
(25/76), and 13.7% (7/51) of the LC units showed significant decrease (Figure 7B) in 
baseline activity in 0.6, 2.5, 10.0 mg/kg MPD treated groups respectively.  
 
Comparing E D10 Baseline Activity To E D1 Baseline Activity O f L C Units Recorded 
F rom Behaviorally Sensitized Rats  
 The baseline activity on ED10 and ED1 recorded from behaviorally sensitized 
rats was compared and summarized in Table 4. A total of 66.6% (6/9), 71.4% (15/21), 
and 82.1% (32/39) of the LC units significantly changed their baseline activity in the 0.6, 
2.5, and 10.0 mg/kg MPD treated behaviorally sensitized subgroup respectively. A total 
of 33.3% (3/9), 52.3% (11/21), and 69.3% (27/39) of LC units significantly increased 
(critical ratio test, C.R. > +1.96) their baseline firing rates, while 33.3% (3/9), 19.1% 
(4/21), and 12.8% (5/39) of LC units significantly decreased (critical ratio test, C.R. > -
1.96) their baseline activity on ED10 compared to their saline baseline activity on ED1 in 
behaviorally sensitized rats from 0.6, 2.5, and 10.0 mg/kg MPD treated groups 
respectively.  
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Table 4: Effect Of MPD On The Baseline Activity Of L C Units On E D10 Compared To The 
Baseline Activity On E D1 In Behavioral Sensitization And Tolerance Rats 
 
This table summarizes the effect of 0.6, 2.5, and 10.0 mg/kg MPD on the baseline activity of LC 
units on ED10 compared to the baseline activity on EDI on 69 LC units recorded from rats 
exhibiting behavioral sensitization and on 124 LC units recorded from rats exhibiting behavioral 
tolerance.  
 
G roups    Behavioral    Units   Increase    Decrease   No change   
0.6 mg/kg 
MPD   Sensitization    9   3 (33.3%)   3 (33.3%)   3 (33.3%)  
   Tolerance    57   11 (19.3%)   17 (29.8%)   29 (50.9%)  
                 
2.5 mg/kg 
MPD   Sensitization   21   11 (52.3%)   4 (19.1%)   6 (28.6%)  
   Tolerance   55   19 (34.5%)   21 (38.2%)   15 (27.3%)  
                 
10.0 mg/kg 
MPD   Sensitization   39   27 (69.3%)   5 (12.8%)   7 (17.9%)  
   Tolerance   12   8 (66.7%)   2 (16.6%)   2 (16.6%)  
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Comparing E D10 Baseline Activity To E D1 Baseline Activity O f L C Units Recorded 
F rom Behaviorally Tolerant Rats  
The baseline activity on ED10 and ED1 recorded from behaviorally tolerant rats 
were compared and summarized in Table 4. A total of 49.1% (28/57), 72.7% (40/55), and 
83.3% (10/12) of the LC units significantly changed their baseline activity in the 0.6, 2.5, 
and 10.0 mg/kg MPD treated behaviorally tolerant subgroup respectively. A total of 
19.3% (11/57), 34.5% (19/55), and 66.7% (8/12) of LC units exhibited a significant 
increase (critical ratio test, C.R. > +1.96) in their baseline firing rates, while 29.8% 
(17/57), 38.2% (21/55), and 16.6% (2/12) of LC units exhibited a significant decrease 
(critical ratio test, C.R. > -1.96) in their baseline activity on ED10 compared to their 
baseline activity on ED1 in behaviorally tolerant rats from 0.6, 2.5, and 10.0 mg/kg MPD 
treated groups respectively.  
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F igure 7: Representative Sequential F requency F iring Rates Of The Baseline Of Two L C 
Units On E D1 Compared To The Baseline On E D10 
 
This figure summarizes the representative sequential frequency firing rates of the baseline of two 
LC units on ED1 compared to the baseline on ED10 following six daily 10.0 mg/kg MPD 
injections and three washout days. The top graph (A) shows the LC unit that exhibited an increase 
in its baseline firing rate activity on ED10 following six daily 10.0 mg/kg MPD injections and 
three washout days compared to the baseline activity on ED1. The bottom graph (B) shows the 
LC unit that exhibited a decrease in baseline firing rate activity on ED10 following six daily 10.0 
mg/kg MPD injections and three washout days compared to the baseline activity on ED1. Insert: 
superimpose of 20 spikes sorted in the same template on ED1 and ED10 respectively.  
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Comparing The E ffect O f Rechallenge MPD On E D10 With The E ffect O f The 
Initial MPD Exposure On E D1 
 The effect of rechallenge administration of MPD on ED10 was compared to the 
effect of initial administration of MPD on ED1. A total of 53% (35/66), 67.1% (51/76), 
and 90.2% (46/51) of the recorded LC units responded significantly by changing their 
firing to 0.6, 2.5, and 10.0 mg/kg MPD respectively (Table 2C, MPD ED10 vs. MPD 
ED1). A total of 31.8% (21/66), 38.2% (29/76), and 60.8% (31/51) of the recorded LC 
units exhibited a further significant increase (critical ratio test, C.R. > +1.96) in their 
activity on ED10 compared to ED1 (Figure 8A), while 21.2% (14/66), 28.9% (22/76), 
and 29.4% (15/51) of the recorded LC units exhibited a significant decrease (critical ratio 
test, C.R. > -1.96) in their activity on ED10 compared to ED1 (Figure 8B) post 0.6, 2.5, 
and 10.0 mg/kg MPD exposure respectively. The further significant increase of LC 
neuronal activity on ED10 compared to ED1 after MPD administration indicates 
neurophysiological sensitization. The further significant decrease or no change of LC 
neuronal activity following MPD rechallenge on ED10 indicates neurophysiological 
tolerance.  
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Comparing The E ffect O f Rechallenge MPD On E D10 To The Initial MPD 
Exposure On E D1 In L C Units Recorded F rom Behaviorally Sensitized Rats 
 The effect of rechallenge MPD on ED10 compared to the initial MPD exposure 
on ED1 in LC units recorded from behaviorally sensitized rats were compared and 
summarized in Table 5. A total of 69 rats were recorded from behaviorally sensitized rats 
following 0.6 (N = 9), 2.5 (N = 21), and 10.0 (N = 39) mg/kg MPD respectively (Table 5) 
; 88.9% (8/9), 76.2% (16/21), and 89.7% (35/39) of the LC units significantly changed 
their activity on ED10 following rechallenge MPD compared to their activity following 
acute MPD exposure on ED1 in 0.6, 2.5, and 10.0 mg/kg MPD treated groups 
respectively. A total of 77.8% (7/9), 47.6% (10/21), and 56.4% (22/39) of LC units 
showed neurophysiological sensitization (critical ratio test, C.R. > +1.96), while 11.1% 
(1/9), 28.6% (6/21), and 33.3% (13/39) of the recorded LC units showed 
neurophysiological tolerance (critical ratio test, C.R. > -1.96) in behaviorally sensitized 
rats from 0.6, 2.5, and 10.0 mg/kg MPD treated groups respectively. 
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Table 5: Effect Of MPD On L C Units On E D10 Compared To E D1 In Behavioral 
Sensitization And Tolerance Rats 
 
This table summarizes the effect of 0.6, 2.5, and 10.0 mg/kg MPD on ED10 compared to that on 
ED1 on 69 LC units recorded from rats exhibiting behavioral sensitization and on 124 LC units 
recorded from rats exhibiting behavioral tolerance. 
 
G roups    Behavioral    Units   Increase    Decrease   No change   
0.6 mg/kg 
MPD   Sensitization    9   7 (77.8%)   1 (11.1%)   1 (11.1%)  
   Tolerance    57   14 (24.5%)   13 (22.8%)   30 (52.7%)  
                 
2.5 mg/kg 
MPD   Sensitization   21   10 (47.6%)   6 (28.6%)   5 (23.8%)  
   Tolerance   55   19 (34.5%)   16 (29.1%)   20 (36.4%)  
                 
10.0 mg/kg 
MPD   Sensitization   39   22 (56.4%)   13 (33.3%)   4 (10.3%)  
   Tolerance   12   9 (75%)   2 (16.7%)   1 (8.3%)  
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Comparing The E ffect O f Rechallenge MPD On E D10 To The Initial MPD 
Exposure On E D1 In L C Units Recorded F rom Behaviorally Tolerant Rats 
 The effect of rechallenge MPD on ED10 compared to the initial MPD exposure 
on ED1 in LC units recorded from behaviorally tolerant rats were also compared and 
summarized in Table 5. A total of 124 LC units were recorded from behaviorally tolerant 
rats following 0.6 (N = 57), 2.5 (N = 55), and 10.0 (N = 12) mg/kg MPD respectively 
(Table 5); 47.3% (27/57), 63.6% (35/55), and 91.7% (11/12) of the LC units significantly 
changed their activity on ED10 following rechallenge MPD compared to their activity 
following acute MPD exposure on ED1 to 0.6, 2.5, and 10.0 mg/kg MPD treated groups 
respectively. A total of 24.5% (14/57), 34.5% (19/55), and 75% (9/12) of LC units 
showed neurophysiological sensitization (critical ratio test, C.R. > +1.96), while 22.8% 
(13/57), 29.1% (16/55), and 16.7% (2/12) of the recorded LC units showed 
neurophysiological tolerance (critical ratio test, C.R. > -1.96) in behaviorally tolerant rats 
from 0.6, 2.5, and 10.0 mg/kg MPD treated groups respectively. 
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F igure 8: Representative Sequential F requency F iring Rates Of Two L C Units Following 
Acute And Chronic 10.0 mg/kg MPD 
 
Both graphs show the neuronal unit activity after 60 minutes of saline (baseline activity), 
followed by an additional 60 minutes post 10.0 mg/kg MPD on ED1, and finally by another 60 
minutes post 10.0 mg/kg MPD on ED10. Arrow indicates the time of 10.0 mg/kg MPD 
administration. In the top graph (A), the acute effect of 10.0 mg/kg MPD on ED1 results in an 
increase in neuronal unity activity compared to ED1 baseline activity. The effect of MPD 
administration on ED10 (after six daily MPD injections and three washout days of no drugs) 
results in a further increase in neuronal activity compared to the initial MPD activity on ED1. 
This response is classified as neurophysiological sensitization. In the bottom graph (B), the acute 
effect of 10.0 mg/kg MPD on ED1 results in an increase in LC neuronal unit firing rate compared 
to ED1 baseline activity. The effect of MPD administration on ED10 (after six daily MPD 
injections and three washout days of no drugs) results in a lower response to MPD when 
compared to the initial MPD activity on ED1. This neuronal unit activity is classified as 
neurophysiological tolerance.  
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DISC USSI O N 
 
 The psychostimulant, methylphenidate is one of the most commonly prescribed 
drugs for the treatment of ADHD, as it works to reduce the symptoms of inattention, 
????????????????????????????????????????????????? ????????????????????? ????????????
are still being investigated. The primary neuropharmacological effect of MPD is that it 
binds to transporters that are responsible for the reuptake of neurotransmitters from the 
synaptic cleft to the presynaptic terminal (Biedermann and Spencer, 1999; Drouin et al., 
2006, Kuczenski and Segal, 2002; Pliszka et al., 1996; Volkow et al., 1995, 2005). 
Norepinephrine imbalance is thought to implicate the pathophysiology of ADHD. The 
locus coeruleus is a major source of NE in the mammalian brain and participates in a 
variety of brain functions (Amaral and Sinnamon, 1977; Moore and Bloom, 1979; Olpe 
et al., 1985). Several studies have shown that NE or the activation of the LC can 
transform the processing of incoming sensory information in the primary sensory circuits 
of the mammalian brain (Devilbiss and Waterhouse, 2000, 2004; Lecas 2004; 
Waterhouse et al., 1998) indicating that the dysfunction in the LC noradrenergic system 
may be responsible for distractibility and inattentiveness seen in those who suffer from 
ADHD. MPD binds to NE transporters and prevents the clearance of NE from the 
synaptic cleft back to presynaptic terminals. Blocking NE reuptake by its transporter 
results in elevated levels of NE in the synaptic cleft that may account for the observed 
therapeutic effects of MPD (Kuczenski and Segal, 2002; Volkow et al., 1995, 2005). 
Therefore, the electrophysiological properties of LC neurons and animal behavior 
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following acute and chronic dose response of MPD were recorded simultaneously in this 
study.  
 The main behavioral findings of this study indicate that chronic administration of 
the same dose of MPD elicited behavioral sensitization in some rats and behavioral 
tolerance in other rats. Acute and chronic injections of saline (control) and 0.6 mg/kg 
MPD did not have a significant effect on the ra????????????????????????????????? ?????
MPD dose group elicited significant increases in behavioral activity to acute exposure but 
elicited significant decreases in behavioral activity to chronic exposure. The 10.0 mg/kg 
MPD dose group showed a significant increase in behavioral activity following acute 
MPD exposure on ED1 and showed further significant increases in behavioral activity 
following rechallenge MPD on ED10.  Once the rats were separated, the rats that elicited 
behavioral sensitization for all dose groups showed a significant increase in behavioral 
activity on ED10 compared to ED1 and the rats that elicited behavioral tolerance showed 
further significant increases in behavioral activity to acute MPD exposure in each dose 
groups when compared to the rats that elicited behavioral sensitization.  
 The main electrophysiological findings of this study show that saline (control) did 
not have a significant effect on the LC neuronal activity either. Most of the LC units 
exhibited increasing firing rates after acute and chronic MPD administration in a dose 
dependent manner. The 0.6 mg/kg MPD dose group had the lowest number of LC units 
responding to acute MPD, while the 10.0 mg/kg dose group had the highest number of 
LC units responding to acute MPD. After 0.6 mg/kg MPD administration, the majority of 
LC units responded to acute MPD by attenuating their firing activity rate. However, after 
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2.5 and 10.0 mg/kg MPD, the majority of LC units responded to acute MPD by 
increasing their firing activity rate. Overall, increasing the MPD dose from 0.6 to 10.0 
mg/kg, demonstrated more units responded by changing their baseline on ED10 (after six 
daily MPD injections and three washout days) compared to their baseline on ED1. These 
changes in baseline activity have been suggested to be in response to withdrawal or 
expectation (Algahim et al., 2009; Bergheim et al., 2012; Lee et al., 2011). The majority 
of LC units increased their neuronal firing activity rate after rechallenge MPD on ED10 
compared to the effects of MPD on ED1 however, the neuronal response to 10.0 mg/kg 
MPD did not show significant changes when comparing rechallenge MPD on ED10 to 
MPD on ED1, therefore it is possible to assume a ceiling effect for the neuronal 
responses that may have been observed (Medes-Gomes et al, 2011, Park et al., 2004).  
The LC neuronal population recorded from behaviorally sensitized rats responded to 
acute MPD on ED1 and MPD rechallenge on ED10 significantly different from the 
neuronal activity recorded from behaviorally tolerant rats. This confirms our hypothesis 
that the same dose of repetitive MPD exposure elicits behavioral sensitization in some 
rats and behavioral tolerance in others and that the rats that elicited behavioral 
sensitization responded significantly different to acute and chronic MPD exposure from 
the rats that elicited behavioral tolerance.   
 Based on the responses to acute and chronic MPD, it is possible to classify 
different types of neurophysiological sensitization and tolerance. LC units that exhibited 
an increase, or decrease in neuronal activity to MPD on ED1 and exhibited a further 
increase, or further decrease in neuronal activity to MPD rechallenge on ED10 are said to 
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show neurophysiological sensitization. LC units that did not respond to acute MPD on 
ED1 but did have a significant response after repetitive MPD exposure on ED10 are said 
to express neurophysiological sensitization. Similarly, different types of 
neurophysiological tolerance were seen. LC units that exhibited a significant response to 
MPD on ED1 but did not respond to MPD rechallenge on ED10 are said to show 
neurophysiological tolerance. Lastly, LC units that exhibited the opposite effect after 
MPD rechallenge on ED10 compared to their response to MPD on ED1 are said to 
express neurophysiological tolerance.  
 Previous studies, (Devilbliss and Berridge, 2006; Lacroix and Ferron, 1988; Olpe 
et al., 1985) showed that MPD administration elicited a decrease in LC neuronal firing 
activity rate in anesthetized rats. This was explained by the inhibitory feedback of 
presynaptic ?2-adrenergic autorecpetors (Lacroix and Ferron, 1988). The increase of LC 
neuronal firing activity rate in our freely moving rats can be explained by other 
mechanisms. The first mechanism to explain the increase of LC neuronal firing activity 
rate in our freely moving, un-anesthetized rats is that LC neurons are phasically activated 
by a variety of sensory stimuli during waking hours (Aston-Jones and Bloom, 1981). The 
sensory feedback from behaviors elicited by MPD may point to the activation of LC 
neurons (Aston-Jones et al., 1991a). This is apparently absent in anesthetized conditions. 
Secondly, the LC receives projections from various brain regions that leads to the release 
of a wide range of neurotransmitters including opiates, GABA, glutamate, epinephrine, 
and serotonin (Aston-Jones et al., 1991b). The neurotransmitters interaction with LC 
neurons could be the other possible explanation for the increase in neuronal firing activity 
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rate seen by MPD in freely behaving rats. The correlation between these 
neurotransmitters needs further elucidation and should be investigated in future studies.  
 Chronic MPD administration could result in an assortment of changes at the 
molecular, behavioral, and neuronal levels. Repeated psychostimulant exposure may 
produce long lasting molecular and cellular changes in the central nervous system, such 
as altered protein synthesis, gene modulation in dopaminergic signaling systems and 
increased dendritic spine populations (Carrey and Wilkinson, 2011; Kim et al., 2009; 
Nestler, 2004) which may play a role in the process of establishing addiction (Dafny and 
Yang, 2006; Fernandez-Espejo and Rodriguez-Espinosa, 2011). It is commonly known 
that both dopamine and norepinephrine systems are involved in the effect of MPD. It has 
been reported that there is a reciprocal interaction between the DA and NE systems 
(Guiard et al., 2008a).  A decrease of DA neurons in the ventral tegmental area (VTA) 
has been postulated to increase the firing activity rate of NE neurons in the LC (Guiard et 
al., 2008a) The inhibitory effect of the DA system could explain the different responses 
recorded of LC units to MPD on ED10 compared with ED1. VTA neurons contain both 
D1 and D2 DA receptors, which are both affected by MPD. When DA D1 receptors are 
activated they elicit an excitatory effect, while the DA D2 receptors elicit an inhibitory 
effect (Jones and Dafny, 2013).  It would be beneficial to continue our study by adding 
experimental day 11 and introduce DA D1 and DA D2 antagonist. On ED11, we should 
resume recording for 60 minutes after saline injection and follow it by either a DA D1 or 
DA D2 antagonist and continue to record activity for 20 minutes. The rats should then be 
given their designated dose of saline (control) or MPD (0.6, 2.5, and 10.0 mg/kg) 
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identical to that given on ED1 and record for an additional 60 minutes. This would allow 
for further elucidation in understanding the correlation between the VTA DA neurons and 
LC NE neurons in eliciting sensitization or tolerance in response to MPD exposure.  
 In conclusion, this study provided evidence that when conducting any type of 
research involving psychostimulant exposure, it is important to evaluate neuronal activity 
based on behavior to find any correlations between drug dose, firing activity, and 
behavioral activity. The current study showed that the LC neuronal population activity 
recorded from rats expressing behavioral sensitization to acute and chronic MPD 
responded differently to those LC units recorded from rats expressing behavioral 
tolerance. Also, the same repetitive dose of MPD that elicited behavioral sensitization in 
some rats and behavioral tolerance in other rats is an important observation that MPD 
users and practitioners need to take into consideration. 
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